Helena Hansen et al., "Whiteout: How Racial Capitalism Changed the Color of Opioids in America" (U California Press, 2023)
Dec 5, 2024
auto_awesome
David Herzberg, co-author and historian specializing in drug policy's intersection with race and class, dives deep into the impact of racial capitalism on the opioid crisis. He discusses how a dual drug policy creates disparities, with punitive measures for marginalized communities versus compassionate care for the privileged. The conversation highlights the evolution of the opioid landscape, examines systemic issues like ignorance and privilege, and underscores the need for equitable interventions. Herzberg also emphasizes the power of narrative in reshaping public perceptions and combating stigma around addiction.
Racial capitalism underpins the biotech industry's exploitation of communities through a dual drug policy that favors white individuals over marginalized groups.
The podcast illustrates how America’s drug policies reflect and reinforce historical racial inequities, impacting healthcare access for affected communities.
Media narratives around drug addiction influence public perception, often portraying white users as victims while criminalizing marginalized populations.
Deep dives
Understanding Racial Capitalism
Racial capitalism is characterized by the accumulation of wealth from cheap labor organized along racial hierarchies, a concept outlined by Cedric Robinson. This framework provides insight into how the current biotech industry also profits through racialized consumption rather than just labor exploitation. The drug policies in the United States have created a bifurcated system that penalizes drug use in marginalized communities while offering medicalize, compassionate care for the same substances to wealthier, predominantly white populations. This enduring system highlights the intersectionality of race, class, and the long-standing impacts of colonialism and exploitation in shaping modern-day health care and drug laws.
The Segregated Nature of Drug Policy
The podcast discusses the emergence of a racially segmented drug policy in the U.S., illustrating how it historically discriminated against Black, brown, and lower-income communities. Specific examples given include the contrasting societal responses to drug use where white communities receive empathy and treatment, whereas marginalized groups face criminalization and harsh penalties. The authors draw connections between historical injustices in drug legislation and contemporary disparities in drug-related healthcare access, emphasizing how these policies perpetuate cycles of poverty and abuse. The authors further advocate for changes in drug policy that recognize and rectify these long-standing inequities.
Case Studies of the Opioid Crisis
Using the opioid crisis as a case study, the podcast illustrates the complex relationship between drug policy and racial discrimination. Three phases of opioid policy are discussed: the initial marketing of oxycodone, the reintroduction of opioids for addiction treatment, and finally, the resurgence of heroin in the market. These transitions reveal how medicalization and criminalization of drug use have been selectively applied based on race, showing that societal compassion is often reserved for white users while others face severe punishment. This disparity not only reflects historical biases but also calls for a restructuring of drug policy to incorporate equity and justice for all communities affected by addiction.
The Role of Media in Shaping Narratives
The media plays a crucial role in shaping public perception surrounding drug use and addiction, often portraying white individuals as victims while condemning marginalized groups as criminals. The podcast highlights the contrasting media narratives that have emerged from different drug crises, stressing the need for journalists to approach these subjects with empathy and accuracy. Additionally, there is an acknowledgment that a new generation of journalists is emerging, eager to tell stories that challenge traditional narratives associated with drugs and addiction. This shift in storytelling is seen as an opportunity to foster more compassionate understandings of the complexities surrounding drug use across racial lines.
Hope and the Future of Drug Policy
The podcast concludes with a reflection on potential future developments in drug policy, particularly amidst changing political climates. There is an acknowledgment that while historical patterns of racialized drug policy persist, the rise of organized, community-led movements advocating for harm reduction and equitable healthcare suggests a shift. Activism focused on the dignity and rights of individuals who use drugs presents a transformative opportunity to address systemic inequities deeply rooted in the fabric of society. The co-authors emphasize the importance of collective action and social consciousness in driving meaningful change in drug policy that extends compassion and support to all communities.
The phrase "racial capitalism" was used by Cedric Robinson to describe an economy of wealth accumulation extracted from cheap labor, organized by racial hierarchy, and justified through white supremacist logics. Now, in the twenty-first century, the biotech industry is the new capitalist whose race-based exploitation engages not only labor but racialized consumption. This arrangement is upheld through US drug policy, which over the past century has created a split legal system—one punitive system that criminalizes drug use common among Black, Brown, and lower-income communities and another system characterized by compassion and care that medicalizes, and thus legalizes, drug use targeted to middle-class White people.
In the award-winning book Whiteout: How Racial Capitalism Changed the Color of Opioids in America(U California Press, 2023), a trio of authors—Helena Hansen, Jules Netherland, and David Herzberg—explain how this arrangement came to pass, what impacts it has, and what needs to be done. This remarkable book won the 2023 Rachel Carson Book Prize from the Society for the Social Studies of Science.
This interview was a collaborative effort among Professor Laura Stark and graduate students at Vanderbilt University in the course, “American Medicine & the World.” Please email Laura with any feedback on the interview or questions about how to design collaborative interview projects for the classroom.